9NY3 | pdb_00009ny3

LR4-488 peptide NMR structure

PDB DOI: https://doi.org/10.2210/pdb9NY3/pdb
BMRB: 31237

Classification: DE NOVO PROTEIN
Organism(s): synthetic construct
Expression System: Escherichia coli
Mutation(s): No

Deposited: 2025-03-26 Released: 2025-04-02
Deposition Author(s): Fry, D.C., Burk, M.J.
Funding Organization(s): Not funded

Experimental Data Snapshot

Method: SOLUTION NMR
Conformers Calculated: 40
Conformers Submitted: 15
Selection Criteria: structures with the lowest energy

wwPDB Validation 3D Report Full Report

This is version 1.1 of the entry. See complete history.

Literature

Overcoming Immune Checkpoint Inhibitor Resistance with Potent, Selective Dual alpha v beta 6/8 Inhibitors Based on Engineered Lasso Peptides.

Lechner, A., Jordan, P.A., Machado da Cruz, G.C., Lamson, J., Gordon, J., Okada, B.K., Anderson, K., Chaudhari, R., Rosario, C.J., Mikesell, J., McPhee, S.A., Burk, M.J.

(2025) J Am Chem Soc 147: 32522-32536

PubMed: 40891737 Search on PubMed
DOI: https://doi.org/10.1021/jacs.5c06142
Primary Citation Related Structures:
9NWZ, 9NY3

PubMed Abstract:
Integrins αvβ6 and αvβ8 in the tumor microenvironment (TME) have been shown to activate immunosuppressive TGF-β, which serves as an important mechanism for immune checkpoint inhibitor resistance in a range of tumors. In this study, we demonstrate the utility of lasso peptides as versatile scaffolds for the design of new therapeutics. A series of highly potent and selective dual αvβ6/8 inhibitors were engineered through a combination of epitope scanning, computational design, and directed evolution, whereby inhibition was fine-tuned for two out of the eight related RGD-integrin receptors. NMR structures of two lasso peptide dual integrin inhibitors are provided. Facile conjugation chemistry with a small-molecule albumin binder afforded half-life extended lasso peptide analogs, including 19 , which was fully characterized and shown to robustly and durably halt growth and regress anti-mPD-1-resistant ovarian and triple negative breast cancer tumors in mice when dosed in combination with the checkpoint inhibitor. These studies show that dual inhibition of αvβ6/8 integrins expressed in the TME represents an auspicious tumor-specific strategy to overcome TGF-β-driven resistance and enhance the antitumor efficacy of immune checkpoint inhibitors. Our ability to produce lasso peptides with high titers in fermenters has enabled the first detailed demonstration of their drug-like properties, including tunable in vivo pharmacokinetics and efficacy, thus paving the way for future advances using this promising modality derived from nature.